report.object
AI models for pharma and biotech R&D
Expert-reviewed from public records, platform data, primary sources, and private research beyond AI search. Use /api/v1/reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD/sample before purchase, then download PDF, JSON, or Markdown after checkout.
page.markdown
AI models for pharma and biotech R&D.md
# AI models for pharma and biotech R&D
Pharma and biotech R&D AI should be evaluated as an experiment-capacity allocator: the model earns budget when it changes which targets, molecules, assays, biomarkers or IND/CTA-supporting analyses consume scarce validation slots.
## Object
| field | value |
| ---------------- | --------------------------------------------- |
| report_id | RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD |
| schema_version | 2026-05-28 |
| last_updated_at | 2026-06-01 |
| category | MODELS |
| sector | Life sciences |
| region | GLOBAL |
| confidence_score | 0.85 |
| source_count | 20 |
| evidence_count | 22 |
## Endpoints
| action | endpoint |
| ------------ | ------------------------------------------------------------------------ |
| summary | /api/v1/reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD |
| sample | /api/v1/reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD/sample |
| schema | /api/v1/reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD/schema |
| quote | /api/v1/reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD/quote |
| purchase | /checkout/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD?view=agent |
| versions | /api/v1/reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD/versions |
| changelog | /api/v1/reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD/changelog |
| monitor | /api/v1/monitors?report_id=RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD |
| mcp_resource | colophon://reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD/sample |
## Coverage
| field | value |
| -------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| category | MODELS |
| sector | Life sciences |
| region | GLOBAL |
| topics | AI drug discovery, pharma R&D, wet-lab validation, model validation, translational evidence |
| source_classes | fda_guidance, regulatory_principles, research_paper, model_report, company_announcement, company_docs, omics_platform_docs, omics_cloud_docs, regulatory_guideline, regulatory_guidance, data_integrity_guidance, benchmark_paper, vendor_directory |
| update_cadence | Weekly |
## Sample JSON
```json
{
"report_id": "RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD",
"slug": "ai-models-pharma-biotech-rd",
"schema_version": "2026-05-28",
"title": "AI models for pharma and biotech R&D",
"abstract": "Pharma and biotech R&D AI should be evaluated as an experiment-capacity allocator: the model earns budget when it changes which targets, molecules, assays, biomarkers or IND/CTA-supporting analyses consume scarce validation slots.",
"category": "MODELS",
"sector": "Life sciences",
"region": "GLOBAL",
"topics": [
"AI drug discovery",
"pharma R&D",
"wet-lab validation",
"model validation",
"translational evidence"
],
"last_updated_at": "2026-06-01T00:00:00Z",
"source_count": 20,
"evidence_count": 22,
"confidence_score": 0.85,
"web_url": "/r/ai-models-pharma-biotech-rd/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD",
"sample_endpoint": "/api/v1/reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD/sample",
"inventory_endpoint": "/api/v1/reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD/inventory",
"full_endpoint": "/api/v1/reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD/full",
"schema_endpoint": "/api/v1/reports/RPT_LIFE_SCIENCES_AI_MODELS_PHARMA_BIOTECH_RD/schema",
"redaction": {
"status": "sample",
"paid_sections_redacted": true,
"preview_limits": [
"summary",
"table_of_contents",
"evidence_profile"
]
},
"coverage": {
"category": "MODELS",
"sector": "Life sciences",
"region": "GLOBAL",
"topics": [
"AI drug discovery",
"pharma R&D",
"wet-lab validation",
"model validation",
"translational evidence"
],
"source_classes": [
"fda_guidance",
"regulatory_principles",
"research_paper",
"model_report",
"company_announcement",
"company_docs",
"omics_platform_docs",
"omics_cloud_docs",
"regulatory_guideline",
"regulatory_guidance",
"data_integrity_guidance",
"benchmark_paper",
"vendor_directory"
]
},
"confidence": {
"overall_confidence": 0.85,
"source_quality": 0.88,
"source_recency": 0.86,
"source_density": 0.83,
"claim_verifiability": 0.84,
"geographic_coverage": 0.78,
"known_gaps": [
"The strongest model papers prove scientific capability, not programme-level probability of technical or clinical success.",
"Private pharma datasets, failed experiments and decision logs are rarely public.",
"Vendor pipeline claims require caution until candidate progression and experimental replication are visible.",
"No public source in this report supplies a production assay-capacity, cycle-time or programme-budget benchmark across comparable buyer workflows."
]
},
"document": {
"object": "report_document",
"schemaVersion": "2026-05-28",
"title": "AI models for pharma and biotech R&D",
"subtitle": "Predictions are abundant; validated experiment slots are scarce.",
"abstract": "Pharma and biotech R&D AI should be evaluated as an experiment-capacity allocator: the model earns budget when it changes which targets, molecules, assays, biomarkers or IND/CTA-supporting analyses consume scarce validation slots.",
"category": "MODELS",
"sector": "Life sciences",
"region": "GLOBAL",
"topics": [
"AI drug discovery",
"pharma R&D",
"wet-lab validation",
"model validation",
"translational evidence"
],
"sources": [
{
"id": "S1",
"label": "FDA - AI to support regulatory decision-making for drugs and biological products",
"publisher": "FDA",
"sourceClass": "fda_guidance",
"accessedAt": "2026-06-01",
"status": "verified",
"access": "sample",
"originalUrl": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological",
"publicationDate": "2025-01-06",
"transformChain": [],
"provenanceNotes": "Guidance source; verify local applicability before relying on exact obligations.",
"url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological"
},
{
"id": "S2",
"label": "FDA and EMA - Guiding principles of good AI practice in drug development",
"publisher": "FDA",
"sourceClass": "regulatory_principles",
"accessedAt": "2026-06-01",
"status": "verified",
"access": "sample",
"originalUrl": "https://www.fda.gov/about-fda/artificial-intelligence-drug-development/guiding-principles-good-ai-practice-drug-development",
"transformChain": [],
"url": "https://www.fda.gov/about-fda/artificial-intelligence-drug-development/guiding-principles-good-ai-practice-drug-development"
},
{
"id": "S3",
"label": "Nature - Accurate structure prediction of biomolecular interactions with AlphaFold 3",
"publisher": "Nature",
"sourceClass": "research_paper",
"accessedAt": "2026-06-01",
"status": "verified",
"access": "sample",
"originalUrl": "https://www.nature.com/articles/s41586-024-07487-w",
"publicationDate": "2024-05-08",
"transformChain": [],
"provenanceNotes": "Study evidence; verify population, endpoint, workflow and local acceptance fit before using as production proof.",
"url": "https://www.nature.com/articles/s41586-024-07487-w"
},
{
"id": "S4",
"label": "Chai-1 technical report",
"publisher": "Chai Discovery",
"sourceClass": "model_report",
"accessedAt": "2026-06-01",
"status": "verified",
"access": "sample",
"originalUrl": "https://chaiassets.com/chai-1/paper/technical_report_v1.pdf",
"publicationDate": "2024-09-09",
"transformChain": [],
"url": "https://chaiassets.com/chai-1/paper/technical_report_v1.pdf"
}
],
"evidence": [
{
"id": "E1",
"sourceId": "S1",
"claimIds": [
"C1"
],
"summary": "FDA draft guidance covers AI used to produce information or data intended to support regulatory decision-making about safety, effectiveness or quality for drugs.",
"status": "verified",
"confidence": 0.88,
"access": "sample"
},
{
"id": "E2",
"sourceId": "S2",
"claimIds": [
"C1"
],
"summary": "FDA and EMA good AI practice principles give drug developers a regulatory credibility frame for AI across development.",
"status": "verified",
"confidence": 0.86,
"access": "sample"
},
{
"id": "E3",
"sourceId": "S3",
"claimIds": [
"C2"
],
"summary": "AlphaFold 3 predicts structures of biomolecular interactions across proteins, nucleic acids, small molecules, ions and modified residues, widening the model route for drug discovery.",
"status": "verified",
"confidence": 0.88,
"access": "sample"
},
{
"id": "E4",
"sourceId": "S4",
"claimIds": [
"C2"
],
"summary": "Chai-1 presents a multimodal foundation model for molecular structure prediction, adding competitive evidence beyond a single model family.",
"status": "verified",
"confidence": 0.82,
"access": "sample"
}
],
"claims": [
{
"id": "C1",
"statement": "Pharma and biotech model buying should start with credibility evidence because FDA and EMA now provide AI-practice principles and FDA draft guidance for regulatory-decision support.",
"confidence": 0.86,
"evidenceIds": [
"E1",
"E2"
],
"access": "sample"
},
{
"id": "C2",
"statement": "Structure and molecular foundation models have become serious diligence inputs, but they do not replace experimental validation.",
"confidence": 0.86,
"evidenceIds": [
"E3",
"E4"
],
"access": "sample"
}
],
"colophon": {
"checkedAt": "2026-06-01",
"latestRevisionAt": "2026-06-01T00:00:00Z",
"reviewStandard": "expert_human_reviewed",
"kinetics": {
"speed": "moderate",
"impact": 0.9,
"momentum": 0.8,
"businessImpact": "R&D models depend on experiment capacity: predictions matter only when they change testable portfolio decisions.",
"rateOfChange": "Prospective validation, experiment-yield evidence and model-access terms make diligence packets unstable across portfolio reviews.",
"from": "single-task QSAR, docking and literature tools",
"toward": "routes linking prediction, experiment, assay, omics and regulatory evidence"
},
"watch": [],
"gapAnalysis": "Programme-level R&D telemetry linking model-selected targets, molecules, assays and biomarkers to replication, hit-to-lead cycle time, assay failure rates, capacity cost, translational fit and candidate progression."
},
"body": {
"sections": [
{
"id": "executive-summary",
"title": "Executive summary",
"access": "sample",
"claimIds": [
"C1",
"C2"
],
"evidenceIds": [
"E3",
"E4",
"E1"
],
"blocks": [
{
"id": "executive-summary-narrative",
"evidenceIds": [
"E3",
"E4",
"E1"
],
"type": "section_narrative",
"lead": "Pharma R&D AI is now an experiment-capacity allocation decision: the model worth funding is the one that proves it changes which targets, molecules, assays, biomarkers or IND/CTA-supporting analyses consume scarce validation slots, not the one that produces the most plausible predictions.",
"body": [
"Structure prediction and molecular foundation model papers show expanded modelling capability [E3, E4], while synthesis, wet-lab assays, omics runs, translational review and regulatory credibility remain the constrained resources. The strategic question is therefore not which model can predict more; it is which model deserves permission to spend scarce experimental capacity.",
"A strong retrospective benchmark can still worsen portfolio allocation when it sends better-looking but weakly testable compounds, targets or biomarkers into the same assay bottleneck [E15].",
"The private-eval denominator is experiment yield: hit quality per assay panel, failed synthesis avoided, cycle time to kill or redesign, biomarker reproducibility, translational decision quality and credibility evidence for any submission-supporting analysis. Public lab-execution evidence is directional here, not a published ROI benchmark [E16].",
"The winning vendor or internal platform may still have frontier models, proprietary data and large compute [E6, E7]. The paid proof is narrower: each model-generated target, binder, property or biomarker must show the experiment it displaced, the result it returned and the next programme decision it improved."
],
"detail": [
"Make private evals replay recent programme choices and then run prospectively: baseline decision, model recommendation, experiment chosen or displaced, assay or omics result, scientist correction and next-cycle update.",
"Do not pay for prediction volume, leaderboard rank or platform breadth unless it converts into higher-quality experimental queues, faster kill calls or stronger translational and regulatory evidence."
]
},
{
"id": "board-decision-table",
"title": "The buying decision",
"evidenceIds": [
"E3",
"E4",
"E1"
],
"type": "table",
"columns": [
{
"key": "question",
"label": "Question",
"align": "left"
},
{
"key": "answer",
"label": "Answer",
"align": "left"
},
{
"key": "move",
"label": "Action",
"align": "left"
}
],
"rows": [
{
"question": "What is the object of approval?",
"answer": "An experiment-capacity allocation right for named target, molecule, assay, biomarker or IND/CTA-supporting analysis slots.",
"move": "Require each model to state which experiment it consumes or displaces and what kill, redesign or advance decision it informs."
},
{
"question": "Which model goes first?",
"answer": "The model aimed at a costly design-make-test-analyse bottleneck where archived decisions, assay outcomes and scientist corrections already exist.",
"move": "Run replay tests, then a prospective batch, before letting the model reprioritize lead optimization, target validation or translational biomarker work."
},
{
"question": "What remains blocked?",
"answer": "Predicted structures, molecules or biomarkers without physical-validity screening [E15], omics provenance [E8, E9], reviewer correction and validation evidence [E1, E11].",
"move": "Keep them out of the prioritized wet-lab queue and out of submission-supporting analyses until the experiment-yield record is complete."
}
]
}
]
},
{
"id": "what-changed",
"title": "What changed",
"access": "sample",
"dek": "Public evidence is now structured enough to define private approval tests.",
"claimIds": [
"C1",
"C2"
],
"evidenceIds": [
"E1",
"E3",
"E4"
],
"blocks": [
{
"id": "what-changed-narrative",
"evidenceIds": [
"E1",
"E3",
"E4"
],
"type": "section_narrative",
"lead": "Prediction abundance now meets scarce validation capacity across chemistry, biology, translational research and regulatory evidence.",
"body": [
"Model capability is no longer the only bottleneck. Structure-prediction and molecular foundation model evidence widens the set of plausible targets, structures and molecules, but synthesis, assays, omics validation, translational interpretation and regulatory credibility decide whether that extra optionality improves a programme [E3, E4].",
"Contract for an experiment-yield scorecard by target, molecule, biomarker or analysis: baseline choice, AI recommendation, experiment chosen or displaced, wet-lab or omics result, next-cycle learning, cycle time and kill, redesign or advance outcome.",
"For model-led R&D workflows, the approval record has to connect source data, accepted output, reviewer action, retained audit and lifecycle evidence before prediction volume or staffing claims matter."
]
},
{
"id": "trigger-table",
"title": "Triggers that change approval timing",
"evidenceIds": [
"E1",
"E3",
"E4"
],
"type": "table",
"columns": [
{
"key": "trigger",
"label": "Trigger",
"align": "left"
},
{
"key": "why_now",
"label": "Why it matters",
"align": "left"
},
{
"key": "buyer_action",
"label": "Decision use",
"align": "left"
}
],
"rows": [
{
"trigger": "FDA AI drug-development guidance",
"why_now": "Regulatory decision-support AI has a named credibility route [E1].",
"buyer_action": "Classify which model outputs may touch submission-supporting evidence."
},
{
"trigger": "ICH M15 model-informed evidence",
"why_now": "ICH M15 supplies MAP/MAR and model-risk discipline for model-informed drug development; verify exact publication, adoption and implementation metadata before relying on date-specific timing [E11].",
"buyer_action": "Ask whether the vendor can produce submission-grade model evidence, not only discovery benchmarks."
},
{
"trigger": "Regulated lab data integrity",
"why_now": "Part 11 and Annex 11 controls decide whether AI-touched lab and omics records can support regulated work [E12, E13].",
"buyer_action": "Put audit trail, access control, backup, supplier oversight and change-control clauses into the validation plan."
},
{
"trigger": "Nonclinical data integrity",
"why_now": "GLP data-integrity rules add retention and traceability pressure for nonclinical evidence [E14].",
"buyer_action": "Keep traceability, retention and reviewer evidence separate from model-performance proof."
},
{
"trigger": "Foundation-model progress",
"why_now": "Structure and molecular models can change experiment choice [E3, E4].",
"buyer_action": "Retest on archived programmes and current assays."
},
{
"trigger": "Industrial compute and data platforms",
"why_now": "Public leaders show compute and platform investment [E6, E7], while lab-loop evidence still needs task-level proof [E10].",
"buyer_action": "Treat data rights, compute, assay capacity and decision logs as diligence requirements, not public-source proof."
}
]
},
{
"id": "route-definition-callout",
"title": "Route definition",
"evidenceIds": [
"E1"
],
"type": "callout",
"tone": "neutral",
"body": "Route means the approved path from work to accepted output: the source set, data boundary, model or vendor channel, tools, reviewer, evidence record and reapproval trigger that make an AI result usable."
}
]
},
{
"id": "decision-map",
"title": "Decision map",
"access": "sample",
"dek": "Workflow approval changes by authority, source boundary and proof burden.",
"claimIds": [
"C1",
"C2"
],
"evidenceIds": [
"E1"
],
"blocks": [
{
"id": "decision-map-narrative",
"evidenceIds": [
"E1"
],
"type": "section_narrative",
"lead": "Fund pharma R&D AI models only when they earn the right to allocate scarce experimental capacity.",
"body": [
"The decision map should start with a scientific decision record from source data to model output, experiment, reviewer decision and retained evidence: what source record is read, what output is drafted, who approves it, where it is stored and what event forces reapproval.",
"A system can pass a low-risk support test and still fail production work: source evidence, accepted output, integration state, exception handling, reviewer burden and downstream rework have to hold together.",
"The useful vendor question is whether the system can make the named task inspectable, reversible and measurable inside the operating record."
]
},
{
"id": "route-selection-table",
"title": "Workflow selection",
"evidenceIds": [
"E1"
],
"type": "table",
"columns": [
{
"key": "route",
"label": "Workflow",
"align": "left"
},
{
"key": "accepted_output",
"label": "Accepted work",
"align": "left"
},
{
"key": "gate",
"label": "Approval gate",
"align": "left"
},
{
"key": "buyer_rule",
"label": "Approval rule",
"align": "left"
}
],
"rows": [
{
"route": "Target and biology prioritization",
"accepted_output": "Ranked target hypothesis with source evidence, uncertainty and validation experiment.",
"gate": "Data lineage, disease context, orthogonal evidence and scientist review.",
"buyer_rule": "Proceed when the model changes experiment selection, not slide quality."
},
{
"route": "Structure and molecule design",
"accepted_output": "Candidate structure, binding hypothesis or molecule design sent to assay.",
"gate": "Model limitations and physical-validity screen [E15].",
"buyer_rule": "Measure experimental hit quality and cycle time."
},
{
"route": "Translational and omics route",
"accepted_output": "Biomarker, cohort, mechanism or stratification hypothesis with reproducible run evidence.",
"gate": "Run ID, sample provenance and workflow version [E8, E9]. Part 11 or Annex 11 control and reviewer sign-off [E12, E13].",
"buyer_rule": "Use versioned omics workflows before model-derived biomarkers enter decisions."
},
{
"route": "Regulatory decision support",
"accepted_output": "AI-derived analysis used to support safety, effectiveness or quality evidence.",
"gate": "Credibility assessment, model risk, Model Analysis Plan or Report, data provenance, model validation and lifecycle control [E1, E11].",
"buyer_rule": "Treat as a regulated evidence route, not research productivity tooling."
}
]
}
]
},
{
"id": "signature-proof",
"title": "Signature proof",
"access": "locked",
"dek": "The decisive proof is whether the workflow survives evidence, audit and rework.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "signature-proof-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "model-evidence-stack",
"title": "Model evidence stack",
"access": "locked",
"dek": "The model is only one layer in an accepted scientific, translational or regulatory-supporting output.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "model-evidence-stack-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "use-case-route-selection",
"title": "Workflow selection",
"access": "locked",
"dek": "Production starts with the lane where output can be accepted or rejected visibly.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "use-case-route-selection-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "evidence-and-benchmarks",
"title": "Evidence fit",
"access": "locked",
"dek": "Public evidence maps to local accepted work.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "evidence-and-benchmarks-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "private-eval-design",
"title": "Private eval design",
"access": "locked",
"dek": "Public evidence chooses the tests; local cases decide production.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "private-eval-design-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "risks-and-controls",
"title": "Risks and controls",
"access": "locked",
"dek": "The main risk is ungoverned action.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "risks-and-controls-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "operating-model",
"title": "Operating model",
"access": "locked",
"dek": "Production ownership crosses clinical, technical, compliance and finance teams.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "operating-model-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "economics",
"title": "Economics",
"access": "locked",
"dek": "Price the accepted work.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "economics-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "implementation-signals",
"title": "Public claim tests",
"access": "locked",
"dek": "Vendor pages seed diligence; local telemetry supplies operating proof.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "implementation-signals-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "vendor-directory",
"title": "Diligence directory",
"access": "locked",
"dek": "Representative vendors and platform RFI anchors to include in diligence.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "vendor-directory-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "recommended-next-steps",
"title": "Recommended next steps",
"access": "locked",
"dek": "A practical workflow can be approved in phases without pretending the whole market is ready.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "recommended-next-steps-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "known-unknowns",
"title": "Known unknowns",
"access": "locked",
"dek": "These gaps should shape diligence rather than delay all buying.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "known-unknowns-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "source-ledger",
"title": "Source ledger",
"access": "locked",
"dek": "Primary public sources and evidence rows behind the workflow analysis.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "source-ledger-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "glossary",
"title": "Glossary",
"access": "sample",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "glossary-table",
"title": "Terms used in this report",
"caption": "Definitions are reader aids, not separate evidence claims.",
"evidenceIds": [],
"type": "table",
"columns": [
{
"key": "term",
"label": "Term",
"align": "left"
},
{
"key": "meaning",
"label": "Plain meaning",
"align": "left"
}
],
"rows": [
{
"term": "Route",
"meaning": "The approved path from work to accepted output: source set, data boundary, model or vendor channel, tools, reviewer, evidence record and reapproval trigger."
},
{
"term": "LLM",
"meaning": "Large language model: a model trained to read and generate text-like tokens."
}
]
}
]
}
]
}
},
"gap_analysis": "Programme-level R&D telemetry linking model-selected targets, molecules, assays and biomarkers to replication, hit-to-lead cycle time, assay failure rates, capacity cost, translational fit and candidate progression.",
"kinetics": {
"speed": "moderate",
"impact": 0.9,
"momentum": 0.8,
"businessImpact": "R&D models depend on experiment capacity: predictions matter only when they change testable portfolio decisions.",
"rateOfChange": "Prospective validation, experiment-yield evidence and model-access terms make diligence packets unstable across portfolio reviews.",
"from": "single-task QSAR, docking and literature tools",
"toward": "routes linking prediction, experiment, assay, omics and regulatory evidence"
},
"watch_signals": [],
"sample_findings": [
"The scarce resource in pharma R&D AI is validated experimental capacity, not model output."
]
}
```